ISSN - 0973-0958

Pediatric Oncall Journal View Article

Omalizumab use in a patient with asthma and hereditary spherocytosis
Sara Completo1, Joana Gomes Vieira1, Patrícia Lipari Pinto1,2, Alexandra Dias2, Anna Sokolova3.
1Child and Youth Department, Hospital Prof. Doutor Fernando Fonseca, E.P.E., Amadora, Portugal,
2Pediatrics Department, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, E.P.E., CAML, Lisbon, Portugal,
3Pneumology Department, Hospital Prof. Doutor Fernando Fonseca, E.P.E., Amadora, Portugal.
Biological drugs are becoming the standard of care in severe refractory allergic diseases. In the case of Omalizumab, it is indicated for severe asthma. Some biological drugs have unexpected effects related to hematotoxicity.
Hereditary spherocytosis is a common cause of hereditary anemia, with heterogeneous manifestations influenced by multiple factors, as exposure to drugs. Our aim was to evaluate possible hematological effect of omalizumab in a case of hereditary spherocytosis.
A 10-year-old boy with hereditary spherocytosis and severe asthma was started on Omalizumab due to several exacerbations and frequent need of oral corticosteroids, along with a decreased respiratory function. After six months, clinical improvement was observed. Simultaneously, there were no changes in hematological parameters.
We report the first case of treatment with Omalizumab in a child with severe asthma and hereditary spherocytosis. In this study, this therapy appears to be safe in hemolytic anemia.

Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0